Fulvestrant: beside a new treatment under test
271 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 3. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT07923214Phase 1Report a problem
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerRecruitingNCT07905001Phase 1Report a problem
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruitingNCT07897721Phase 1Report a problem
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3Report a problem
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingNCT07867262Phase 1Report a problem
- A Phase 1/2a Study of K-1728 in Advanced Solid TumorsRecruitingNCT07861932Phase 1/2Report a problem
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingNCT07857226Phase 2Report a problem
- A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNot yet recruitingNCT07811232Phase 1/2Report a problem
- Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerRecruitingNCT07810088Phase 2Report a problem
- A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid TumorsNot yet recruitingNCT07787520Phase 1Report a problem
- JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast CancerNot yet recruitingNCT07784036Phase 3Report a problem
- A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsRecruitingNCT07767474Phase 1/2Report a problem
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07716046Phase 2Report a problem
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2Report a problem
- A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.RecruitingNCT07666555Phase 2Report a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2Report a problem
- Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruitingNCT07604571Phase 1Report a problem
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2Report a problem
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerRecruitingNCT07558733Phase 1/2Report a problem
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsRecruitingNCT07540572Phase 1Report a problem
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior TreatmentRecruitingNCT07498478Phase 2Report a problem
- Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid TumorNot yet recruitingNCT07480681Phase 1Report a problem
- A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast CancerNot yet recruitingNCT07393321Phase 3Report a problem
- A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast CancerRecruitingNCT07389733Phase 1/2Report a problem
- A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerRecruitingNCT07358377Phase 1Report a problem
- Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.Not yet recruitingNCT07340619Phase 2Report a problem
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingNCT07330544Phase 2Report a problem
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingNCT07318805Phase 1Report a problem
- Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruitingNCT07288359Phase 1/2Report a problem
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingNCT07287917Phase 1/2Report a problem
- A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07235618Phase 2Report a problem
- Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer PatientsRecruitingNCT07235176Phase 1/2Report a problem
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsRecruitingNCT07226349Phase 1Report a problem
- A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.RecruitingNCT07207070Phase 3Report a problem
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2Report a problem
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2Report a problem
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1Report a problem
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsRecruitingNCT07109726Phase 1/2Report a problem
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Phase 3Report a problem
- Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingNCT07037199Phase 2Report a problem
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsRecruitingNCT07029399Phase 1Report a problem
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsRecruitingNCT06998407Phase 1/2Report a problem
- Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyRecruitingNCT06998108Phase 3Report a problem
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT06997029Phase 1Report a problem
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsRecruitingNCT06993844Phase 1/2Report a problem
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruitingNCT06982521Phase 3Report a problem
- Study of TYK-00540 Tablets in Patients With Advanced Solid TumorsRecruitingNCT06950086Phase 1/2Report a problem
- A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT06788197Phase 1/2Report a problem
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsRecruitingNCT06784193Phase 1Report a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Phase 3Report a problem
- BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerRecruitingNCT06756932Phase 1Report a problem
- Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast CancerNot yet recruitingNCT06750848Phase 2Report a problem
- SNV4818 in Participants With Advanced Solid TumorsRecruitingNCT06736704Phase 1/2Report a problem
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2Report a problem
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingNCT06625775Phase 1Report a problem
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2Report a problem
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT06555068Phase 1/2Report a problem
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerRecruitingNCT06515470Phase 1Report a problem
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsRecruitingNCT06431243Phase 1/2Report a problem
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2Report a problem
- Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerRecruitingNCT06341894Phase 2Report a problem
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid TumorsRecruitingNCT06208410Phase 1/2Report a problem
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerRecruitingNCT06202261Phase 1/2Report a problem
- A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerRecruitingNCT06172322Phase 1Report a problem
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingNCT06120283Phase 1Report a problem
- I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast CancersNot yet recruitingNCT05986071Phase 1/2Report a problem
- Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsRecruitingNCT05985655Phase 1/2Report a problem
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2Report a problem
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2Report a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingNCT05894239Phase 3Report a problem
- A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicableReport a problem
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.RecruitingNCT05872347Phase 2Report a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2Report a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingNCT05861830Phase 3Report a problem
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05860465Phase 2/3Report a problem
- Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2Report a problem
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2Report a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2Report a problem
- PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerRecruitingNCT05759546Phase 2Report a problem
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerRecruitingNCT05735080Phase 1/2Report a problem
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2Report a problem
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingNCT05683418Phase 1Report a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingNCT05646862Phase 3Report a problem
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2Report a problem
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2Report a problem
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2Report a problem
- Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2Report a problem
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingNCT05573126Phase 1/2Report a problem
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05504213Phase 1Report a problem
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerRecruitingNCT05455619Phase 1/2Report a problem
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsRecruitingNCT05394103Phase 1/2Report a problem
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingNCT05216432Phase 1Report a problem
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2Report a problem
- The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2Report a problem
- Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR MutationRecruitingNCT04936295Phase 2Report a problem
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast CancerRecruitingNCT04872166Phase 1Report a problem
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingNCT04606446Phase 2Report a problem
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingNCT04557449Phase 2Report a problem
- A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast CancerRecruitingNCT04282031Phase 1/2Report a problem
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2Report a problem